Lymphoma at the extremes of age

Gero-Oncology Nursing Research

PURPOSE/OBJECTIVES

To analyze the development of gero-oncology research through a critical review of nursing and other relevant research as well as the present state of practice.

DATA SOURCES

Journal articles, book chapters, and personal experience.

DATA SYNTHESIS

Cancer in older adults is viewed through two investigative perspectives. The assumptions, questions, theoretical frames, and research design that follow from these investigative perspectives do not adequately meet the need to examine the interplay of responses to aging, cancer, and nursing practice. The mismatch of need, knowledge, and resources marks older adults with cancer as a special population in need of far more sophisticated research. With the synthesis of a new perspective, gero-oncology nursing research becomes age focused, more precisely shaping theoretical, methodologic, and analytic approaches.

CONCLUSIONS

Uniform attachment of chronologic age or other simple age-related variables to investigations, which is the primary consideration of age-related research, is irrelevant for older adults who are diagnosed with, treated for, live with, survive, and die from cancer. Shaping the next phase of gero-oncology research with a focus on age precisely integrates theoretical, methodologic, and analytic approaches through language specific to older adults and cancer.

IMPLICATIONS FOR NURSING

Shifting perspectives in gero-oncology nursing research will better inform future practice.

Establishing a nursing research agenda in gero-oncology

Expanding the evidence base of cancer in the elderly is critical to advance the specialty of geriatric oncology nursing. This article will propose topics for nursing investigation relative to prevention and early detection, response to disease and treatment, and psychosocial responses in the elderly at risk for, or having cancer. International considerations for undertaking nursing research with this special population are also described. Current dilemmas requiring investigation and future demographic implications are highlighted.

Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital

BACKGROUND

The annual incidence of non-Hodgkin lymphoma (NHL) has increased over the past two decades in all age groups, including the elderly. Establishing guidelines for proper care for this segment of the population requires further information.

METHODS

Between January 1993 and April 2002, 187 consecutive patients with NHL who were age 70 years or older were examined as part of the current study. Potential factors implicated in prognosis were analyzed for indolent lymphoma group and aggressive lymphoma group separately.

RESULTS

The median patient age was 75 years (range, 70-90 years), and 83% of the patients examined were male. Fifty-two patients (28%) had indolent lymphoma, and 135 patients (72%) had aggressive lymphoma. The complete remission rate was 33.3% for patients with indolent lymphoma and 35.9% for patients with aggressive lymphoma. Median overall survival was 41.5 months and 23.7 months for the indolent and aggressive lymphoma groups, respectively. The 1-year and 5-year survival rates were 76% and 32%, respectively, for patients with indolent lymphoma and 62% and 29%, respectively, for patients with aggressive lymphoma. Among patients with indolent lymphoma, poor prognosis was correlated with poor performance status (P = 0.0107), advanced disease stage (P = 0.0222), initial bone marrow involvement (P = 0.0069), and age greater than 80 years (P = 0.0486); however, none of these variables remained statistically significant after multivariate Cox regression. Among patients with aggressive lymphoma, the only prognostic factors that remained after multivariate analysis were performance status (P = 0.018) and age greater than 80 years (P = 0.029). For patients who received at least 2 courses of systemic chemotherapy, an anthracycline-containing regimen did not affect the survival rate in either the indolent lymphoma group (P = 0.81) or the aggressive lymphoma group (P = 0.34). After stratification, it was found that patients with aggressive lymphoma who were in the high-intermediate-risk group (as determined by International Prognostic Index [IPI] score) benefited most from the anthracycline-containing regimen (P = 0.0148).

CONCLUSIONS

Performance status was identified as the major prognostic determinant for elderly patients with aggressive NHL. In addition, it was found that an anthracycline-containing treatment regimen may be especially beneficial for patients in the high-intermediate-risk category as determined by IPI score.